Highlights Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 10:05:11 06/03/2026 pm IST			5-day change	1st Jan Change
67.50 ^GBX	-4.93%		0.00%	+16.38%

24/02	Avacta hails new data supporting proprietary preCision platform	AN
24/02	Avacta Therapeutics Plans FAP-Exd's Clinical Trials After 'Favorable' Experimental Analysis	MT

Highlights

24/02	Avacta hails new data supporting proprietary preCision platform	AN
24/02	Avacta's pre\|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis	CI
04/02	Avacta Therapeutics Announces Two Key Clinical Updates to its Faridoxorubicin Clinical Program	CI
21/01	Avacta Therapeutics Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug Application for the Second Pre\|Cision® Medicine, Fap-Exatecan	CI
21/01	EARNINGS AND TRADING: Kenmare meets guidance, plans to lower costs	AN
21/01	Avacta announces US FDA clearance of the investigational new drug application for the second pre\|CISION medicine, FAP-Exatecan	RE
21/01	Avacta Therapeutics Wins US FDA Nod to Start Early-stage Trial of Cancer Drug FAP-Exd	MT
20/01	EARNINGS AND TRADING: Treatt cuts dividend after "challenging year"	AN
18/12	Avacta Reports New Pharmacology Data for Fap-Exd	CI
18/12	Avacta Therapeutics Announces Faridoxorubicin Phase 1B Cohort Demonstrates Clinically Meaningful Tumor Shailage in Patients with Salivary Metals Cancer	CI
25/25/25	Avacta Presents First Preclinical Data from Dual Payload Pre\|Cision® Medicines At the 2025 Aacr-Nci-Eortc International Conference on Molecular Targets	CI
19/25/19	Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre\|CISION®? Platform at the European Society of Medical Oncology Annual Congress	CI
30/25/30	Avacta Group Plc Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	EARNINGS: Suspension damages Enwell Energy; forex hurts Hemogenyx	AN
30/25/30	Earnings Flash (AVCT.L) Avacta Group Reports H1 Revenue GBP56,000	MT
01/25/01	Avacta completes GBP2 million Coris Bioconcept sale	AN
01/25/01	Avacta Group Concludes Sale of Rapid Diagnostic Tests Business	MT
29/25/29	Trupcr Europe Limited and 3B Blackbio Dx Limited completed the acquisition of CorisBioConcept SPRL from Avacta Group Plc.	CI
30/25/30	Avacta Therapeutics to Present New FAP Dox Data at the European Society for Medical Oncology Congress	CI
28/25/28	Trupcr Europe Limited and 3B Blackbio Dx Limited entered into a definitive agreement to acquire CorisBioConcept SPRL from Avacta Group Plc for £2.8 million.	CI
28/25/28	Avacta Group sells Coris to transition to therapeutics business	AN
28/25/28	Avacta Group to Divest Coris Bioconcept for GBP2 Million	MT
03/25/03	IntelliAM wins order; Schroder BSC mulls options	AN
19/25/19	Avacta Group plc Announces New Response in the FAP-Dox Phase 1B Trial	CI
19/25/19	Journeo in New York deal; Anpario to meet market view	AN